Heterogeneity in retinoic acid signaling in neuroblastomas: Role of matrix metalloproteinases in retinoic acid-induced differentiation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1772, Issue 9, 2007, Pages 1093-1102

  Joshi, Suchitra ^a   Guleria, Rakeshwar S ^a   Pan, Jing ^a   DiPette, Donald ^a   Singh, Ugra S ^a  

^a TEXAS A AND M UNIVERSITY SYSTEM   (United States)

Author keywords

Matrix metallo proteinases; Neuroblastoma; Retinoic acid; Rho GTPases; Tissue transglutaminase

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE; NEUROMODULIN; PROTEIN CDC42; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RAC1 PROTEIN; RETINOIC ACID; TAU PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL HETEROGENEITY; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; NERVE FIBER GROWTH; NEUROBLASTOMA CELL; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; CDC42 GTP-BINDING PROTEIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MATRIX METALLOPROTEINASES; NEURITES; NEUROBLASTOMA; SIGNAL TRANSDUCTION; TRETINOIN;

EID: 34548172288     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2007.05.009     Document Type: Article

References (61)

1. Reynolds C.P., Matthay K.K., Villablanca J.G., and Maurer B.J. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 197 (2003) 185-192
2. Santiago A., and Erickson C.A. Ephrin-B ligands play a dual role in the control of neural crest cell migration. Development 129 (2002) 3621-3632
3. N.M. Le Douarin, and G. Kalcheim, The neural crest, ed., Cambridge Universtiy Press, Cambridge, 1999.
4. Ross R.A., Biedler J.L., and Spengler B.A. A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors. Cancer Lett. 197 (2003) 35-39
5. Maris J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatr. 17 (2005) 7-13
6. Kuroda T., Honna T., Morikawa N., Kitano Y., Fuchimoto Y., Terawaki K., Kumagai M., Tsunematsu Y., Masaki H., Matsuoka K., and Saeki M. Tumor cell dynamics and metastasis in advanced neuroblastoma. Pediatr. Surg. Int. (2005) 1-5
7. Pession A., and Tonelli R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr. Cancer Drug Targets 5 (2005) 273-283
8. Schwab M. MYCN in neuronal tumours. Cancer Lett. 204 (2004) 179-187
9. Nguyen T., Hocker J.E., Thomas W., Smith S.A., Norris M.D., Haber M., Cheung B., and Marshall G.M. Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells. Biochem Biophys Res. Commun. 302 (2003) 462-468
10. Reynolds C.P., Wang Y., Melton L.J., Einhorn P.A., Slamon D.J., and Maurer B.J. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med. Pediatr. Oncol. 35 (2000) 597-602
11. Joshi S., Guleria R., Pan J., DiPette D., and Singh U.S. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 25 (2006) 240-247
12. Farina A.R., Masciulli M.P., Tacconelli A., Cappabianca L., De Santis G., Gulino A., and Mackay A.R. All-trans-retinoic acid induces nuclear factor kappaB activation and matrix metalloproteinase-9 expression and enhances basement membrane invasivity of differentiation-resistant human SK-N-BE 9N neuroblastoma Cells. Cell Growth Differ. 13 (2002) 343-354
13. Guzhova I., Hultquist A., Cetinkaya C., Nilsson K., Pahlman S., and Larsson L.G. Interferon-gamma cooperates with retinoic acid and phorbol ester to induce differentiation and growth inhibition of human neuroblastoma cells. Int. J. Cancer 94 (2001) 97-108
14. Carpentier A., Balitrand N., Rochette-Egly C., Shroot B., Degos L., and Chomienne C. Distinct sensitivity of neuroblastoma cells for retinoid receptor agonists: evidence for functional receptor heterodimers. Oncogene 15 (1997) 1805-1813
15. Pan J., Kao Y., Joshi S., Jeethendran S., DiPette D., and Singh U. Activation of Rac1 by phosphatidylinositol 3 kinase in vivo: role in activation of mitogen activated protein kinase (MAPK) pathways and retinoic acid induced neuronal differentiation of SH-SY5Y cells. J. Neurochem. 10 (2005) 1-13
16. Tucholski J., Lesort M., and Johnson G.V. Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience 102 (2001) 481-491
17. Overall C.M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol. 22 (2002) 51-86
18. Himelstein B.P., Canete-Soler R., Bernhard E.J., Dilks D.W., and Muschel R.J. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 14 (1994) 246-258
19. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89 (1997) 1260-1270
20. Chantrain C.F., Shimada H., Jodele S., Groshen S., Ye W., Shalinsky D.R., Werb Z., Coussens L.M., and Declerk Y.A. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 64 (2004) 1675-1686
21. Ribatti D., Marimpietri D., Pastorino F., Brignole C., Nico B., Vacca A., and Ponzoni M. Angiogenesis in neuroblastoma. Ann. N. Y. Acad. Sci. 1028 (2004) 133-142
22. Sugiura Y., Shimada H., Seeger R.C., Laug W.E., and DeClerck Y.A. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 58 (1998) 2209-2216
23. Cheng Y., Dong Q., Sun L.R., Yang C.M., and Jiang B.X. Correlation between expression of MMP-2, MMP-9, TIMP-2, TIMP-1 and metastasis of neuroblastoma. Zhonghua Zhongliu Zazhi 27 (2005) 164-166
24. Ara T., Fukuzawa M., Kusafuka T., Komoto Y., Oue T., Inoue M., and Okada A. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J. Pediatr. Surg. 33 (1998) 1272-1278
25. Noujaim D., van Golen C.M., van Golen K.L., Grauman A., and Feldman E.L. N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells. Oncogene 21 (2002) 4549-4557
26. Singh U.S., Pan J., Kao Y.L., Joshi S., Young K.L., and Baker K.M. Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J. Biol. Chem. 278 (2003) 391-399
27. Grandinetti K.B., Spengler B.A., Biedler J.L., and Ross R.A. Loss of one HuD allele on chromosome #1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells. Oncogene 25 (2006) 706-712
28. Lindskog M., Spenger C., Jarvet J., Graslund A., and Kogner P. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma. J. Natl. Cancer Inst. 96 (2004) 1457-1466
29. Cornaglia-Ferraris P., Ponzoni M., Montaldo P., Mariottini G.L., Donti E., Di Martino D., and Tonini G.P. A new human highly tumorigenic neuroblastoma cell line with undetectable expression of N-myc. Pediatr. Res. 27 (1990) 1-6
30. Savini I., D'Angelo I., Annicchiarico-Petruzzelli M., Bellincampi L., Melino G., and Avigliano L. Ascorbic acid recycling in N-myc amplified human neuroblastoma cells. Anticancer Res. 18 (1998) 819-822
31. Miyashita M., Ohnishi H., Okazawa H., Tomonaga H., Hayashi A., Fujimoto T.T., Furuya N., and Matozaki T. Promotion of neurite and filopodium formation by CD47: roles of integrins, Rac, and Cdc42. Mol. Biol. Cell 15 (2004) 3950-3963
32. Sarner S., Kozma R., Ahmed S., and Lim L. Phosphatidylinositol 3-kinase, Cdc42, Rac1 act downstream of Ras in integrin-dependent neurite outgrowth in N1E-115 neuroblastoma cells. Mol. Cell. Biol. 20 (2000) 158-172
33. Chuang T.H., Hahn K.M., Lee J.D., Danley D.E., and Bokoch G.M. The small GTPase Cdc42 initiates an apoptotic signaling pathway in Jurkat T lymphocytes. Mol. Biol. Cell 8 (1997) 1687-1698
34. Crocker S.J., Hayley S.P., Smith P.D., Mount M.P., Lamba W.R., Callaghan S.M., Slack R.S., and Park D.S. Regulation of axotomy-induced dopaminergic neuron death and c-Jun phosphorylation by targeted inhibition of cdc42 or mixed lineage kinase. J. Neurochem. 96 (2006) 489-499
35. Reynolds C.P., and Lemons R.S. Retinoid therapy of childhood cancer. Hematol./Oncol. Clin. North Am. 15 (2001) 867-910
36. Livingstone A., and Mairs R.J. N-myc amplification and its relationship to experimental therapy. J. Neuro-oncol. 31 (1997) 33-39
37. Teitz T., Lahti J.M., and Kidd V.J. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J. Mol. Med. 79 (2001) 428-436
38. Han S., Wada R.K., and Sidell N. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res. 61 (2001) 3998-4002
39. Thiele C.J., Reynolds C.P., and Israel M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313 (1985) 404-406
40. Brodeur G.M., Seeger R.C., Schwab M., Varmus H.E., and Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224 (1984) 1121-1124
41. Taguchi K., Yoshida K., Sasaki F., and Fujinaga K. Two transcription factors, E1AF and N-myc, correlate with the invasiveness of neuroblastoma cell lines. Jpn. J. Cancer Res. 88 (1997) 394-400
42. Valentijn L.J., Koppen A., van Asperen R., Root H.A., Haneveld F., and Versteeg R. Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res. 65 (2005) 3136-3145
43. Liu T., Bohlken A., Kuljaca S., Lee M., Nguyen T., Smith S., Cheung B., Norris M.D., Haber M., Holloway A.J., Bowtell D.D., and Marshall G.M. The retinoid anticancer signal: mechanisms of target gene regulation. Br. J. Cancer 93 (2005) 310-318
44. Liu Y., Lee M.O., Wang H.G., Li Y., Hashimoto Y., Klaus M., Reed J.C., and Zhang X. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. 16 (1996) 1138-1149
45. Zhang X.K., Liu Y., and Lee M.O. Retinoid receptors in human lung cancer and breast cancer. Mutat. Res. 350 (1996) 267-277
46. Karlsson J., Edsjo A., Pahlman S., and Pettersson H.M. Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia. Mol. Cancer Ther. 4 (2005) 1128-1135
47. Voigt A., and Zintl F. Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells. Med. Pediatr. Oncol. 40 (2003) 205-213
48. Kirimoto A., Takagi Y., Ohya K., and Shimokawa H. Effects of retinoic acid on the differentiation of chondrogenic progenitor cells, ATDC5. J. Med. Dent. Sci. 52 (2005) 153-162
49. Nie D., Ishikawa Y., Yoshimori T., Wuthier R.E., and Wu L.N. Retinoic acid treatment elevates matrix metalloproteinase-2 protein and mRNA levels in avian growth plate chondrocyte cultures. J. Cell. Biochem. 68 (1998) 90-99
50. Thier M., Roeb E., Breuer B., Bayer T.A., Halfter H., and Weis J. Expression of matrix metalloproteinase-2 in glial and neuronal tumor cell lines: inverse correlation with proliferation rate. Cancer Lett. 149 (2000) 163-170
51. von Marschall Z., Riecken E.O., and Rosewicz S. Induction of matrix metalloprotease-1 gene expression by retinoic acid in the human pancreatic tumour cell line Dan-G. Br. J. Cancer 80 (1999) 935-939
52. Chambaut-Guerin A.M., Herigault S., Rouet-Benzineb P., Rouher C., and Lafuma C. Induction of matrix metalloproteinase MMP-9 (92-kDa gelatinase) by retinoic acid in human neuroblastoma SKNBE cells: relevance to neuronal differentiation. J. Neurochem. 74 (2000) 508-517
53. Zuo J., Ferguson T.A., Hernandez Y.J., Stetler-Stevenson W.G., and Muir D. Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin sulfate proteoglycan. J. Neurosci. 18 (1998) 5203-5211
54. Krekoski C.A., Neubauer D., Graham J.B., and Muir D. Metalloproteinase-dependent predegeneration in vitro enhances axonal regeneration within acellular peripheral nerve grafts. J. Neurosci. 22 (2002) 10408-10415
55. Uhm J.H., Dooley N.P., Oh L.Y., and Yong V.W. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 22 (1998) 53-63
56. Oh L.Y., Larsen P.H., Krekoski C.A., Edwards D.R., Donovan F., Werb Z., and Yong V.W. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J. Neurosci. 19 (1999) 8464-8475
57. Ferguson T.A., and Muir D. MMP-2 and MMP-9 increase the neurite-promoting potential of Schwann cell basal laminae and are upregulated in degenerated nerve. Mol. Cell. Neurosci. 16 (2000) 157-167
58. Heine W., Conant K., Griffin J.W., and Hoke A. Transplanted neural stem cells promote axonal regeneration through chronically denervated peripheral nerves. Exp. Neurol. 189 (2004) 231-240
59. Nordstrom L.A., Lochner J., Yeung W., and Ciment G. The metalloproteinase stromelysin-1 (transin) mediates PC12 cell growth cone invasiveness through basal laminae. Mol. Cell. Neurosci. 6 (1995) 56-68
60. Le Douarin N.M., and Smith J. Development of the peripheral nervous system from the neural crest. Annu. Rev. Cell Biol. 4 (1988) 375-404
61. Maschhoff K.L., and Baldwin H.S. Molecular determinants of neural crest migration. Am. J. Med. Genet. 97 (2000) 280-288